BACKGROUND: This study explores whether genomic profiles of colorectal liver metastasis (CRLM) patients with early onset (EO, < 50 years old) and screening age (SA) primary diagnosis are associated with overall survival (OS). METHODS: All patients undergoing hepatectomy between 2002 and 2017 were identified and tumor specimens with next-generation sequencing data were cataloged. Gene and signaling-level alterations were checked for association with OS from primary diagnosis accommodating for left-truncated survival. RESULTS: Of 1822 patients, 333 were sequenced-127 (38%) EO-CRLM and 206 (62%) SA-CRLM patients. More aggressive features presented in EO-CRLM patients-synchronous metastatic presentation (83% vs. 75%, p < 0.001) and primary node-positive disease (71% vs. 61%, p < 0.001). The median OS from primary diagnosis was 11.8 years (95% confidence interval = 7.94-NA). Five-year OS did not differ by age (p = 0.702). On multivariable analysis, altered APC (EO-CRLM: [hazard ratio [HR] = 0.37, p = 0.018] vs. SA-CRLM:[HR = 0.61, p = 0.260]), BRAF (EO-CRLM:[HR = 4.38, p = 0.007] vs. SA-CRLM:[HR = 4.78, p = 0.032]), and RAS-TP53 (EO-CRLM:[HR = 2.82, p = 0.011] vs. SA-CRLM:[HR = 2.35, p = 0.003]) associated with OS. CONCLUSIONS: Despite bearing more aggressive features, EO-CRLM patients had similar genomic profiles and survival as SA-CRLM patients. Better performance status in younger patients leading to increased treatment tolerance may partly explain this. As screening and treatment strategies from older patients are applied to younger patients, genomic predictors of biology identified historically in older cohorts could apply to EO patients.
BACKGROUND: This study explores whether genomic profiles of colorectal liver metastasis (CRLM) patients with early onset (EO, < 50 years old) and screening age (SA) primary diagnosis are associated with overall survival (OS). METHODS: All patients undergoing hepatectomy between 2002 and 2017 were identified and tumor specimens with next-generation sequencing data were cataloged. Gene and signaling-level alterations were checked for association with OS from primary diagnosis accommodating for left-truncated survival. RESULTS: Of 1822 patients, 333 were sequenced-127 (38%) EO-CRLM and 206 (62%) SA-CRLM patients. More aggressive features presented in EO-CRLM patients-synchronous metastatic presentation (83% vs. 75%, p < 0.001) and primary node-positive disease (71% vs. 61%, p < 0.001). The median OS from primary diagnosis was 11.8 years (95% confidence interval = 7.94-NA). Five-year OS did not differ by age (p = 0.702). On multivariable analysis, altered APC (EO-CRLM: [hazard ratio [HR] = 0.37, p = 0.018] vs. SA-CRLM:[HR = 0.61, p = 0.260]), BRAF (EO-CRLM:[HR = 4.38, p = 0.007] vs. SA-CRLM:[HR = 4.78, p = 0.032]), and RAS-TP53 (EO-CRLM:[HR = 2.82, p = 0.011] vs. SA-CRLM:[HR = 2.35, p = 0.003]) associated with OS. CONCLUSIONS: Despite bearing more aggressive features, EO-CRLM patients had similar genomic profiles and survival as SA-CRLM patients. Better performance status in younger patients leading to increased treatment tolerance may partly explain this. As screening and treatment strategies from older patients are applied to younger patients, genomic predictors of biology identified historically in older cohorts could apply to EO patients.
Authors: Efsevia Vakiani; Manickam Janakiraman; Ronglai Shen; Rileen Sinha; Zhaoshi Zeng; Jinru Shia; Andrea Cercek; Nancy Kemeny; Michael D'Angelica; Agnes Viale; Adriana Heguy; Philip Paty; Timothy A Chan; Leonard B Saltz; Martin Weiser; David B Solit Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: Andrew M D Wolf; Elizabeth T H Fontham; Timothy R Church; Christopher R Flowers; Carmen E Guerra; Samuel J LaMonte; Ruth Etzioni; Matthew T McKenna; Kevin C Oeffinger; Ya-Chen Tina Shih; Louise C Walter; Kimberly S Andrews; Otis W Brawley; Durado Brooks; Stacey A Fedewa; Deana Manassaram-Baptiste; Rebecca L Siegel; Richard C Wender; Robert A Smith Journal: CA Cancer J Clin Date: 2018-05-30 Impact factor: 508.702
Authors: Ashton A Connor; Kate McNamara; Eisar Al-Sukhni; Jacob Diskin; David Chan; Colleen Ash; Lori E Lowes; Alison L Allan; George Zogopoulos; Carol-Anne Moulton; Steven Gallinger Journal: Ann Surg Oncol Date: 2015-12-29 Impact factor: 5.344
Authors: Paolo Goffredo; Alan F Utria; Anna C Beck; Yun Shin Chun; James R Howe; Ronald J Weigel; Jean-Nicolas Vauthey; Imran Hassan Journal: J Gastrointest Surg Date: 2018-10-01 Impact factor: 3.452
Authors: Yun Shin Chun; Guillaume Passot; Suguru Yamashita; Maliha Nusrat; Panagiotis Katsonis; Jonathan M Loree; Claudius Conrad; Ching-Wei D Tzeng; Lianchun Xiao; Thomas A Aloia; Cathy Eng; Scott E Kopetz; Olivier Lichtarge; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2019-05 Impact factor: 12.969
Authors: Johan Gagnière; Aurélien Dupré; Sepideh S Gholami; Denis Pezet; Thomas Boerner; Mithat Gönen; Thomas P Kingham; Peter J Allen; Vinod P Balachandran; Ronald P De Matteo; Jeffrey A Drebin; Rona Yaeger; Nancy E Kemeny; William R Jarnagin; Michael I D'Angelica Journal: Ann Surg Date: 2020-01 Impact factor: 12.969
Authors: Christopher H Lieu; Lindsay A Renfro; Aimery de Gramont; Jeffrey P Meyers; Timothy S Maughan; Matthew T Seymour; Leonard Saltz; Richard M Goldberg; Daniel J Sargent; S Gail Eckhardt; Cathy Eng Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: A Rose Brannon; Efsevia Vakiani; Brooke E Sylvester; Sasinya N Scott; Gregory McDermott; Ronak H Shah; Krishan Kania; Agnes Viale; Dayna M Oschwald; Vladimir Vacic; Anne-Katrin Emde; Andrea Cercek; Rona Yaeger; Nancy E Kemeny; Leonard B Saltz; Jinru Shia; Michael I D'Angelica; Martin R Weiser; David B Solit; Michael F Berger Journal: Genome Biol Date: 2014-08-28 Impact factor: 13.583